Search Results - cd19

4 Results Sort By:
Bivalent, Dual Specific Anti-CD22 Anti-CD19 Chimeric Antigen Receptors (CARs)
Abstract: Chimeric antigen receptors (CARs) combine an antibody-based binding domain (and single chain fragment variable region, scFv) with T cell receptor signaling domains (CD3 zeta with a costimulatory domain, typically CD28 or 41BB). When T cells express CARs, they are activated in a major histocompatibility complex- (MHC) independent manner to...
Published: 4/8/2024   |   Inventor(s): Terry Fry, Crystal Mackall, Rimas Orentas, Haiying Qin, Waleed Haso
Keywords(s): Acute Lymphoblastic Leukemia, ALL, BISPECIFIC, Bivalent, CAR, CD19, CD22, Diffuse Large B-Cell Lymphoma, DLBCL, Dual-Specific Chimeric Antigen Receptors, Fry, Oncology, Pediatric Leukemia, Pediatric Lymphoma
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology
Optimized Monospecific or Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20
Abstract: Patients with chemotherapy-refractory, diffuse large B-cell lymphoma (DLBCL) have poor prognoses. CD19 and CD20 are promising targets for the treatment of B-Cell malignancies. However, despite the initial promising results from anti-CD19 CAR therapy, only 30-35% of patients with DLBCL achieve remissions lasting longer than 2-3 years after...
Published: 8/14/2024   |   Inventor(s): James Kochenderfer, Norris Lam
Keywords(s): act, adoptive cell therapy, Autoimmune, B Cell Malignancies, BICISTRONIC, CAR, CD19, CD20, chimeric antigen receptor, Kochenderfer, Leukemia, lymphoma, Monospecific
Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Immunology, TherapeuticArea > Oncology
Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20
Abstract: CD19 and CD20 are promising targets for the treatment of B-Cell malignancies.  Unfortunately, some clinical studies have shown that there is a loss of CD19 or CD20 expression in various cases of lymphomas and leukemias, particularly after treatment with an agent that targets CD19 (e.g., anti-CD19 CAR-T). However, studies have shown that expression...
Published: 8/14/2024   |   Inventor(s): James Kochenderfer, Shicheng Yang
Keywords(s): act, adoptive cell therapy, B Cell Malignancies, BICISTRONIC, CAR, CD19, CD20, chimeric antigen receptor, Kochenderfer, Leukemia, lymphoma
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics
Dual Specific Anti-CD22 Anti-CD19 Bicistronic Chimeric Antigen Receptors (CARs)
Abstract: Treatment of B-cell acute lymphoblastic leukemia (ALL) and lymphoma using chimeric antigen receptors (CARs) targeting B-cell surface protein CD19 has demonstrated impressive clinical results in children and young adults. Despite the promising results from CD19 CAR therapy, up to 40% of patients, who initially achieve remission, eventually...
Published: 8/14/2024   |   Inventor(s): Haiying Qin, Terry Fry, Crystal Mackall
Keywords(s): Acute Lymphoblastic Leukemia, ALL, BICISTRONIC, CAR, CD19, CD22, Diffuse Large B-Cell Lymphoma, DLBCL, Dual-Specific Chimeric Antigen Receptors, Fry, Oncology, Pediatric Leukemia, Pediatric Lymphoma
Category(s): TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Therapeutics, Collaboration Sought > Collaboration